MedTrace Logo

Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients

NCT00468078 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2016-01-13

No results posted yet for this study

Summary

The purpose of this study is to determine whether F-18 FPCIT is effective and safe radiopharmaceutical for the objective diagnosis of Parkinson's disease.

Conditions

Interventions

PROCEDURE

PET/CT

10min acquisition, 90min after injection of F-18 FPCIT

DRUG

F-18 FPCIT

5mCi, intravenous injection

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Jae Seung Kim, MD · Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2007-09-30
Completion
2007-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00468078 on ClinicalTrials.gov